Background
ASTRO Evidence-Based Guideline on Thoracic Palliative Radiotherapy. Systematic review and practice guideline for RT of symptomatic thoracic malignancies (endobronchial obstruction, superior vena cava syndrome, hemoptysis, chest wall pain) from lung cancer and thoracic metastases. Addresses dose fractionation, brachytherapy, and SBRT options for palliative thoracic indications.
Interventions and follow up
Arm A: N/A — guideline document
Primary endpoint: Symptom palliation, local control, toxicity by fractionation schedule
mFollow up: N/A
Primary endpoint: Symptom palliation, local control, toxicity by fractionation schedule
mFollow up: N/A
Results
Key indications covered: Endobronchial obstruction, SVC syndrome, hemoptysis, chest wall pain, symptomatic mediastinal adenopathy
Hemoptysis palliation: Short-course RT (17–20 Gy/5 fx or 20 Gy/4 fx) achieves 80–90% control
SVCS palliation: 30 Gy/10 or 20 Gy/5 achieves 60–80% response; emergency RT 8 Gy × 1 appropriate
Endobronchial obstruction: Brachytherapy (HDR endobronchial) 10–15 Gy/1–3 effective for proximal lesions
Hypofractionated palliative RT: MXRT/Machester equivalent — 17–20 Gy/5 or 16–20 Gy/4 supported
Hemoptysis palliation: Short-course RT (17–20 Gy/5 fx or 20 Gy/4 fx) achieves 80–90% control
SVCS palliation: 30 Gy/10 or 20 Gy/5 achieves 60–80% response; emergency RT 8 Gy × 1 appropriate
Endobronchial obstruction: Brachytherapy (HDR endobronchial) 10–15 Gy/1–3 effective for proximal lesions
Hypofractionated palliative RT: MXRT/Machester equivalent — 17–20 Gy/5 or 16–20 Gy/4 supported
Adverse events
Main adverse events: Esophagitis (dysphagia, odynophagia): grade ≥2 in 20–30% with 30 Gy/10. Radiation pneumonitis: grade ≥2 in 5–10% for lung fields. Brachytherapy: hemoptysis risk, perforation (<1%).
Conclusions
Short-course hypofractionated RT (17 Gy/2 or 20 Gy/5) is effective for palliation of thoracic symptoms from lung cancer. Longer-course RT (30–39 Gy/10–13) offers similar symptom palliation but requires more visits. Brachytherapy is effective for endobronchial disease. Emergency single-fraction RT is appropriate for SVCS in rapidly deteriorating patients.
Key Limitations
Key Limitations: Evidence base is predominantly non-randomized. Optimal palliative dose for different thoracic symptoms varies by symptom type and expected survival. Concurrent systemic therapy may affect RT tolerance and symptom response.
Clinical Context
Palliative thoracic RT is a core skill for radiation oncologists managing advanced lung cancer. ASTRO, NCCN, and ESMO guidelines support hypofractionated short-course RT (17–20 Gy/5) as appropriate for symptomatic palliation of thoracic malignancy. Integration with systemic IO/targeted therapy requires attention to radiation pneumonitis risk.
References